Volume : 12, Issue : 01, January – 2025
Title:
A REVIEW ON ADVANCEMENTS IN IMMUNOTHERAPY FOR TREATMENT OF CANCER
Authors :
Pradnya V. Lahupanchang, Shubham U. Tikait, Swati P. Deshmukh
Abstract :
Immunotherapy for cancer discuss the development, efficacy, and limitations of immunotherapy as a cancer treatment. They also highlight the potential for new therapies and the need for more research. Immunotherapy is a treatment that uses the body’s immune system to fight cancer. It can involve the use of vaccines, monoclonal antibodies, and other agents to manipulate the immune system. Immunotherapy can be used in combination with other treatments, such as chemotherapy, radiation, and surgery. Immunotherapy can improve survival and quality of life for cancer patients. It can prolong the life expectancy of patients with metastatic cancer. Immunotherapy can be used to treat a wide range of cancers. Immunotherapy can cause severe adverse reactions. Immunotherapy can have a low response rate.The immune system can have difficulty targeting cancer cells. Researchers are developing new ways to predict which patients will respond to immunotherapy. Researchers are testing combinations of immunotherapy with other treatments. Researchers are studying how cancer cells evade the immune system.
Key Words: Immunotherapy, how treat cancer, Immunotherapy Types
Cite This Article:
Please cite this article in press Pradnya V. Lahupanchang et al., A Review On Advancements In Immunotherapy For Treatment Of Cancer ., Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
1. Yanagi Y. Yoshikai Y, Leggett K, Clark SP. Aleksander 1, Mak TW. A human T cell- specific edna close encodes a protein having extensive homology to immunoglobulin chains.
2. Mccarthy, EF The toxins of William H. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 2006, 26, 154-158.
3. Hayre, D.S. 23. Coley’s toxin and spontaneous tumour regression. Clin. Investig. Mod. 2007,30.
4. Kramer, M.G., Masner, M.; Ferreira, F.A., Hoffman, R.M. Bacterial Therapy of Cancer. Promises, Limitations, and Insights for Future Directions, Front. Microbiol. 2018, 9, 16.
5. Oiseth, SJ., Aziz, M.S. Cancer immunotherapy. A brief review of the history, possibilities, and challenges ahead. J. Cancer Metastasis Treat. 2017, 3,250
6. Ribatti, D. The concept of immune surveillance against tumors. The first theories. Oncotarget 2017, 8, 7175-7180.
7. Vivier, E.; Ugolini, S., Blaise, D.; Chabannon, C.; Brossay, L. Targeting natural killer cells and natural killer t cells in cancer. Nat. Rev. Immunol. 2012, 12, 239-252.
8. Jorgensen, N.; Persson, G.; Hviid, T.V.F. The tolerogenic function of regulatoryt cells in pregnancy and cancer. Front. Immunol. 2019, 10, 91.
9. Nishida, N.; Yano, H.; Nishida, T., Kamura, T., Kojiro, M.Angiogenesis in cancer. Vase. Health Risk Manage, 2006, 2, 213-219.
10. Dunn, G.P., Bruce, A.T.; Ikeda, H.; Old, LJ.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
11. Prehn, R.T.; Main, J.M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 1957, 18, 769-778.
12. Oiseth, S.J.; Aziz, M.S. Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead. J. Cancer Metastasis Treat. 2017, 3, 250.
13. Bhatia, A.; Kumar, Y. Cellular and molecular mechanisms in cancer immune escape: A comprehensive review. Expert Rev. Clin. Immunol. 2014, 10, 41-62.
14. Allison JP. Immune checkpoint inhibitors: a revolution in cancer therapy. [Internet]. Bethesda (MD): National Cancer Institute; 2023.
15. Gross, G.; Gorochov, G.; Waks, Institutes Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant. Proc. 1989
16. Coley WB. The treatment of bone starter 200 means of the immune response. JAMA. 1891;16(14):1015-6.
17. Dock G. A case of spontaneous tumor remission following influenza. JAMA. 1896;26(6):361.
18. Blumenthal J, von Leyden E. Vaccination against cancer: a study of the use of autologous tumor tissue. Lancet. 1902;159(4091):807-9.
19. Parakh, S.; Lee, S.T.; Gan, H.K.; Scott, A.M. Radiolabeled Antibodies for Cancer Imaging and Therapy. Cancers 2022, 14, 1454.
20. Sachdeva, M.; Busser, B. W.; Temburni, S.; Jahangiri, B.; Gautron, A.-S.; Maréchal, A.; Juillerat, A.; Williams, A.; Depil, S.; Duchateau, P.; et al. Repurposing endogenous immune pathways totailor and control chimeric antigen receptor Tcell functionality. Nat. Commun. 2019, 10, 5100.